3,0
9 juin 2015
Employé (anonyme)
Employé (actuel)
Recommande
Approbation du PDG
Perspective commerciale
Avantages
Compensation, Big Brands, OTC Switch capability
Inconvénients
The Joint Venture with Novartis is all about cutting costs. The new GSK will be way too lean. I fear the GSK I know and love will be long gone in a few months. The transition will be long and difficult. Many things will fall trought the cracks and GSK will be less customer focused and even more focused on saving a buck. The poor performance of Big Pharma has made life difficult for Consumer Healthcare as we need to help the broader company keep the dividends high.